"10.1371_journal.pone.0146003","plos one","2016-01-11T00:00:00Z","Zafar Zafari; Mohsen Sadatsafavi; Carlo A Marra; Wenjia Chen; J Mark FitzGerald","Institute for Heart and Lung Health (IHLH), Faculty of Medicine, University of British Columbia, Vancouver, Canada; Center for Clinical Epidemiology and Evaluation, Vancouver Coastal Health Institute, University of British Columbia, Vancouver, Canada; Respiratory Medicine Division, Faculty of Medicine, University of British Columbia, Vancouver, Canada; School of Pharmacy, Memorial University of Newfoundland, St. John's, Canada; Collaboration for Outcomes Research and Evaluation, Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, Canada","Conceived and designed the experiments: ZZ MS CAM JMF. Performed the experiments: ZZ MS WC. Analyzed the data: ZZ. Contributed reagents/materials/analysis tools: ZZ MS. Wrote the paper: ZZ MS CAM WC JMF.","The authors have the following interests: J. Mark FitzGerald received a grant from Allergen. His relevant financial activities outside of the present work are from GlaxoSmithKline, AstraZeneca, Novartis, Pfizer, Boehringer-Ingelheim, Altana, Merck, and Topigen. Carlo A. Marra's relevant financial activities outside of the present work are from GlaxoSmithKline, Pfizer, Boehringer-Ingelheim, and Abbvie. There are no patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.","2016","01","Zafar Zafari","ZZ",5,TRUE,4,3,1,5,TRUE,TRUE,FALSE,0,NA,FALSE
